Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Summary<br/> <strong>Background:</strong> The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We rep...

Full description

Bibliographic Details
Main Authors: Oza, A, Cook, A, Pfisterer, J, Embleton, A, Ledermann, J, Pujade-Lauraine, E, Kristensen, G, Carey, M, Beale, P, Cervantes, A, Park-Simon, T, Rustin, G, Joly, F, Mirza, M, Plante, M, Quinn, M, Poveda, A, Jayson, G, Stark, D, Swart, A, Farrelly, L, Kaplan, R, Parmar, M, Perren, T
Format: Journal article
Published: Elsevier 2015

Similar Items